WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 329648
CAS#: 34118-92-8 (HCl)
Description: Acecainide, also known as N-acetylprocainamide and ASL 601, is the N-acetylated metabolite of procainamide. Acecainide is a Class III antiarrhythmic agent. It can be given either intravenously or orally, and is eliminated primarily by renal excretion.
MedKoo Cat#: 329648
Name: Acecainide HCl
CAS#: 34118-92-8 (HCl)
Chemical Formula: C15H24ClN3O2
Exact Mass:
Molecular Weight: 313.826
Elemental Analysis: C, 57.41; H, 7.71; Cl, 11.30; N, 13.39; O, 10.20
Related CAS #: 32795-44-1 (free base)
Synonym: Acecainide; N-acetylprocainamide, ASL 601; ASL-601; ASL601.
IUPAC/Chemical Name: 4'-((2-(Diethylamino)ethyl)carbamoyl)acetanilide monohydrochloride
InChi Key: IYEWBJUCJHKLHD-UHFFFAOYSA-N
InChi Code: InChI=1S/C15H23N3O2.ClH/c1-4-18(5-2)11-10-16-15(20)13-6-8-14(9-7-13)17-12(3)19;/h6-9H,4-5,10-11H2,1-3H3,(H,16,20)(H,17,19);1H
SMILES Code: CC(NC1=CC=C(C(NCCN(CC)CC)=O)C=C1)=O.[H]Cl
1: Harron DW, Brogden RN. Acecainide (N-acetylprocainamide). A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiac arrhythmias. Drugs. 1990 May;39(5):720-40. Review. PubMed PMID: 1693889.
2: Coyle JD, Boudoulas H, Lima JJ. Acecainide pharmacokinetics in normal subjects of known acetylator phenotype. Biopharm Drug Dispos. 1991 Nov;12(8):599-612. PubMed PMID: 1724922.
3: Ghosh SC, Ngiam JS, Seayad AM, Tuan DT, Chai CL, Chen A. Copper-catalyzed oxidative amidation of aldehydes with amine salts: synthesis of primary, secondary, and tertiary amides. J Org Chem. 2012 Sep 21;77(18):8007-15. Epub 2012 Aug 30. PubMed PMID: 22894712.
4: Carter JE, Dutcher JS, Carney DP, Klein LR, Black LA, Erhardt PW. Analysis of procainamide hydrochloride and acecainide hydrochloride in rat feed. J Pharm Sci. 1980 Dec;69(12):1439-40. PubMed PMID: 6162025.
5: Roden DM, Reele SB, Higgins SB, Wilkinson GR, Smith RF, Oates JA, Woosley RL. Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide. Am J Cardiol. 1980 Sep;46(3):463-8. PubMed PMID: 6158263.
6: Vyden JK. Acecainide for ventricular arrhythmias. JAMA. 1982 Feb 5;247(5):581. PubMed PMID: 6172606.
7: Sanna GP. New drugs in the management of ventricular arrhythmias. G Ital Cardiol. 1984 Oct;14(10):788-97. PubMed PMID: 6083894.
8: Bateman DN. Pharmacokinetics and metabolism of the benzamides. Adv Biochem Psychopharmacol. 1982;35:143-62. Review. PubMed PMID: 6183928.
9: Somberg J, Wynn J, Miura D, Torres V, Williams S, Keefe D. N-acetylprocainamide's antiarrhythmic action in patients with ventricular tachycardia. Angiology. 1986 Dec;37(12 Pt 2):972-81. PubMed PMID: 2433972.
10: Somogyi A, Heinzow B. Cimetidine reduces procainamide elimination. N Engl J Med. 1982 Oct 21;307(17):1080. PubMed PMID: 6181402.
11: Atkinson AJ Jr, Lertora JJ, Kushner W, Chao GC, Nevin MJ. Efficacy and safety of N-acetylprocainamide in long-term treatment of ventricular arrhythmias. Clin Pharmacol Ther. 1983 May;33(5):565-76. PubMed PMID: 6188570.
12: Liu XQ, Huang SK. [Combined pharmacokinetic and pharmacodynamic model analysis for procainamide and its metabolite]. Zhongguo Yao Li Xue Bao. 1991 Jan;12(1):7-11. Chinese. PubMed PMID: 1719744.
13: Kabra PM, Chen SH, Marton LJ. Liquid-chromatographic determination of antidysrhythmic drugs: procainamide, lidocaine, quinidine, disopyramide, and propranolol. Ther Drug Monit. 1981;3(1):91-101. PubMed PMID: 7233493.
14: Meisner DJ, Carlson RJ, Gottlieb AJ. Thrombocytopenia following sustained-release procainamide. Arch Intern Med. 1985 Apr;145(4):700-2. PubMed PMID: 2580499.
15: Pirovino M, Karlaganis G, Galeazzi RL. [Steady-state plasma and saliva concentrations of procainamide and N-acetyl-procainamide after a sustained release preparation]. Schweiz Med Wochenschr. 1980 Sep 27;110(39):1415-9. German. PubMed PMID: 6169144.
16: Karol MD, Goodrich S. Metabolite formation pharmacokinetics: rate and extent of metabolite formation determined by deconvolution. Pharm Res. 1988 Jun;5(6):347-51. PubMed PMID: 2469080.
17: Piergies AA, Ruo TI, Jansyn EM, Belknap SM, Atkinson AJ Jr. Effect kinetics of N-acetylprocainamide-induced QT interval prolongation. Clin Pharmacol Ther. 1987 Jul;42(1):107-12. PubMed PMID: 2439251.
18: Boucher M, Dubray C, Paire M, Duchêne-Marullaz P. Comparative effects of procainamide and its N-acetylated metabolite in conscious dogs with atrioventricular block: plasma concentration-response relationships. J Cardiovasc Pharmacol. 1987 Nov;10(5):562-7. PubMed PMID: 2447406.
19: Lahita R, Kluger J, Drayer DE, Koffler D, Reidenberg MM. Antibodies to nuclear antigens in patients treated with procainamide or acetylprocainamide. N Engl J Med. 1979 Dec 20;301(25):1382-5. PubMed PMID: 91972.
20: Ludden TM, Crawford MH, Kennedy GT. N-acetylprocainamide kinetics during intravenous infusions and subsequent oral doses in patients with coronary artery disease and ventricular arrhythmias. Pharmacotherapy. 1985 Jan-Feb;5(1):11-5. PubMed PMID: 2580291.
